Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

被引:0
作者
Trine Zeeberg Buch-Hansen
Lise Bentzen
Steinbjoern Hansen
Morten Hoeyer
Niels Viggo Jensen
Charlotte Saxe
Lisa Sengeloev
机构
[1] Herlev University Hospital,Department of Oncology
[2] Aarhus University Hospital,Department of Oncology
[3] Odense University Hospital,Department of Oncology
来源
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词
PSA response; Palliation; Chemotherapy; Pain;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:295 / 301
页数:6
相关论文
共 123 条
  • [1] Pienta KJ(2005)Advances in prostate cancer chemotherapy: a new era begins CA Cancer J Clin 5 300-318
  • [2] Smith DC(2003)Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 17 3335-3342
  • [3] Ernst DS(2003)Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma Cancer 8 1627-1634
  • [4] Tannock IF(2003)Clinical approaches to osseous metastases in prostate cancer Oncologist 2 161-173
  • [5] Winquist EW(1996)Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 6 1756-1764
  • [6] Venner PM(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 15 1502-1512
  • [7] Reyno L(2008)Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 10 1749-1753
  • [8] Moore MJ(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 15 1513-1520
  • [9] Gravis G(2001)Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial Ann Oncol 9 1259-1264
  • [10] Bladou F(2000)Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor Cancer 3 516-522